Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director

  Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device
  Investment Banker, Samuel Navarro, as Director

Business Wire

IRVINGTON, N.Y. -- March 14, 2014

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind^®, an FDA approved
optical diagnostic device that assists dermatologists in melanoma diagnosis,
today announced the appointment of veteran medical device investment banker
Samuel E. Navarro to the Board of Directors. Mr. Navarro’s appointment brings
MELA’s Board to eight members.

Mr. Navarro brings a wealth of knowledge and industry expertise in finance,
investment banking, mergers and acquisitions, equity research and investment
management experience in the medical device industry. Mr. Navarro is currently
Managing Partner at Gravitas Healthcare, LLC. Before Gravitas, Mr. Navarro was
Managing Director of Cowen & Co. in New York City and head of their Medical
Technology Investment Banking initiatives, leading a team of senior people,
and was responsible for building the franchise across all product categories,
including M&A/Advisory and financing services and products. Before Cowen &
Co., Mr. Navarro spent over four years at The Galleon Group running the
Galleon Healthcare Fund as a Senior Portfolio Manager. He was responsible for
all healthcare investments across all sectors, including pharmaceuticals /
biopharmaceutical industries, medical technology and hospital supplies, and
all areas of healthcare services. Prior to Galleon, Mr. Navarro was Global
Head of Healthcare Investment Banking at ING Barings.

Mr. Navarro has also served or serves on the boards of Arstasis,
MicroTherapeutics, Jomed, Photomedex and Pixelux Entertainment. Mr. Navarro
received an MBA in Finance from The Wharton School at the University of
Pennsylvania, a Master of Science in Engineering from Stanford University and
a Bachelor of Science in Engineering from The University of Texas at Austin.

Mr. Navarro commented, “I am excited to contribute to the MELA Sciences Board
as they execute their U.S. and European commercialization strategy for
MelaFind and develop plans for other global markets. I also look forward to
working with the company to evaluate and develop other potential applications
for their optical diagnostic technology.”

Rose Crane, CEO of MELA Sciences said, “Sam brings a tremendous breadth of
experience, expertise and relationships across the medical device and
healthcare industry and huge enthusiasm regarding MELA Sciences and our
potential. We look forward to the vital insight and guidance Sam will provide
as we move forward.”

Please follow us:

         Twitter:     @MELASciencesIR or @MelaFind
                  StockTwits:   @MELASciencesIR
                  Facebook:     MELA Sciences or MelaFind
                  BoardVote:    MELA

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The flagship product is
MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to
aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a
variety of visible to near-infrared light waves to evaluate skin lesions from
the surface to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA is also
exploring new potential uses for its core imaging technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and may
contain words such as “seeks,” “look forward,” and “there seems” that suggest
future events or trends. These statements are based on our current
expectations and are inherently subject to significant uncertainties and
changes in circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive, market,
regulatory and political factors or conditions affecting the company and the
medical device industry in general, as well as more specific risks and
uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all of these forward-looking statements may
prove to be incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully review its SEC
disclosures available at www.sec.gov and www.melasciences.com.

Contact:

Media
MELA Sciences, Inc.
Diana Garcia Redruello, 212-518-4226
dgarcia@melasciences.com
or
Investors
Catalyst Global
Toni Trigiani, David Collins, 212-924-9800
mela@catalyst-ir.com
 
Press spacebar to pause and continue. Press esc to stop.